The main treatments for moderate to severe plaque psoriasis are biologics, such as anti‐interleukin (IL‐17), anti‐interleukin (IL‐23), and antitumor necrosis factor (TNF‐α), as well as oral agents.9, 10, 11. The gene discussed is IL17A; the disease is psoriasis vulgaris.